The information collection deals with
FDA's patent term restoration regulations on due diligence
petitions for regulatory review period revision. When a patented
product must receive FDA approval before marketing is permitted,
the Patent and Trademark Office (PTO) may add a portion of FDA's
review time to the term of a patent. Petitioners may request
reductions in the regulatory review time if FDA marketing approval
was not pursued with "due diligence."